melanoma
BMS’ Opdivo and Yervoy combination shows outstanding survival rate in cancer patients
October 22, 2018Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, Yervoy, melanoma, opdivo
American pharma firm Bristol-Myers Squibb have announced that more than 53% of patients with advanced melanoma, who were treated with …
NICE recommends Novartis combo as first-ever BRAF-targeted therapy for advanced post-surgery melanoma
September 17, 2018Sales and Marketing Cancer, NICE, Novartis, Tafinlar, mekinist, melanoma, pharma
NICE has taken the decision to recommend the first ever first BRAF-targeted therapy for use on the NHS in England …
BMS’ Opdivo fails to win over NICE as adjuvant melanoma therapy
September 10, 2018Sales and Marketing BMS, NHS, NICE, melanoma, opdivo, pharma
Bristol-Myers Squibb has failed to convince NICE to approve the use of its PD-1 inhibitor immunotherapy Opdivo (nivolumab) as an …
Top Ten most popular articles on Pharmafile.com this week
June 1, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AI, Allergan, AstraZeneca, Cancer, Gilead, HIV, J&J, JJ, google, machine learning, melanoma, pharma, top ten
The first day of June – time for another top ten run-down. It’s been a week somewhat characterised by trial …
Google AI outperforms 58 dermatologists in detecting melanoma
May 30, 2018Research and Development AI< Google, Cancer, melanoma, pharma, skin cancer
An deep learning artificial intelligence system has demonstrated its ability to outperform over 50 human dermatologists in the detection of …
Keytruda continues success with new Phase 3 data in adjuvant melanoma
April 16, 2018Research and Development, Sales and Marketing Cancer, MSD, keytruda, melanoma, pharma, skinc cancer
MSD has revealed new efficacy data for Keytruda (permbrolizumab) as an adjuvant therapy in the treatment of resected, high-risk stage …
Array’s melanoma therapy blasts Roche’s out of water
February 7, 2018Research and Development Array Biopharma, Pierre Fabre, Roche, biotech, drugs, melanoma, pharma, pharmaceutical
Array Biopharma suffered a serious knock back in early 2017 when its plan to commercialise its drug, binimetinib, were derailed …
Melanoma treatment: Novartis posts success, Roche stumbles
September 11, 2017Research and Development, Sales and Marketing Novartis, Roche, biotech, drugs, melanoma, pharma, pharmaceutical
In a perfect example of the competitive nature of the pharmaceutical industry, just as one company posted success in one …
Drug that induces tanning could protect against melanoma
June 16, 2017Medical Communications, Research and Development melanoma, skin cancer, sun
People will often go to extraordinary lengths to achieve tanned skin but researchers have found a potential method that does …
No causal link between Viagra use and melanoma, study finds
May 19, 2017Medical Communications, Research and Development melanoma, viagra
Research from the NYU Langone Medical Center and its Perlmutter Cancer Center, based in New York City, has indicated that …
Researchers identify key trigger in melanoma progression
May 3, 2017Research and Development melanoma
Researchers from life sciences research institute VIB and KU Leuven in Belgium in collaboration with INSERM, the French National Institute …
SMC reverses decision on Opdivo in advanced skin cancer
August 8, 2016Manufacturing and Production, Research and Development SMC, Scottish Medicines Consortium, melanoma, opdivo, skin cancer
The Scottish Medicines Consortium (SMC) has reversed an earlier decision for Bristol-Myers Squibb’s Opdivo (nivolumab) and has now approved recommended …
Amgen skin cancer drug Imlygic rejected by NICE
March 16, 2016Research and Development Amgen, Imlygic, NICE, melanoma, skin cancer
NICE has rejected Amgen’s drug Imlygic (talimogene laherparepvec) in draft as a treatment for advanced melanoma that has spread and …
Merck says US FDA accepts its sBLA for Keytruda
March 8, 2016Manufacturing and Production, Research and Development Merck & Co, US FDA, keytruda, melanoma
US pharma giant Merck & Co said the US Food and Drug Administration (FDA) has accepted for review a new …
BMS criticises Scottish regulator over Opdivo skin cancer ‘no’
March 7, 2016Medical Communications, Research and Development Bristol-Myers Sqibb, NICE, SMC, melanoma, opdivo
Bristol-Myers Squibb says the Scottish Medicines Consortium’s (SMC) decision not to recommend its immunotherapy Opdivo (nivolumab) as a monotherapy for …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
